Every material Form 8-K LISATA THERAPEUTICS, INC. has filed with the SEC since August 04, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
At its November 9, 2026 annual meeting, Lisata Therapeutics stockholders approved the 2026 Equity Incentive Plan, the 2026 Employee Stock Purchase Plan, and a reverse stock split authorization with a ratio between 1-for-5 and 1-for-15. The vote on the Series C preferred stock conversion proposal, which would exceed 20% of outstanding common stock and result in a change of control, was not held and the meeting was adjourned. The conversion vote will resume at a reconvened meeting on November 30, 2026.
2026 Equity Incentive Plan approved with an initial reserve of 44,764,472 shares; 2,924,154 votes for and 1,552,345 against.
2026 Employee Stock Purchase Plan approved with an initial reserve of 3,730,372 shares.
Reverse stock split proposal approved with a ratio to be set by the Board between 1-for-5 and 1-for-15; 7,524,706 votes for.
Series C preferred conversion proposal not voted; reconvened meeting set for November 30, 2026 at 11:00 a.m. Eastern.
Lisata Therapeutics' board increased its size from seven to eight members and appointed Jeffrey Farrow, currently CFO and Chief Strategy Officer of Tarsus Pharmaceuticals, to fill the new seat effective October 13, 2026. Mr. Farrow also joined the Audit Committee, and the board determined he is independent under Nasdaq listing rules.
Appointed effective October 13, 2026 as a Class III director, with an initial term expiring at the 2028 annual meeting
Joins the Audit Committee; the board determined he is independent under Nasdaq Capital Market listing rules
Has been CFO and Chief Strategy Officer of Tarsus Pharmaceuticals since April 2023 and previously served as CFO of Global Blood Therapeutics until its acquisition by Pfizer in December 2022
Lisata Therapeutics acquired Marea Therapeutics on September 17, 2026, issuing 1,793,129 shares of common stock and 211,365.213 shares of Series C convertible preferred stock to Marea stockholders. A concurrent private placement is expected to raise about $225 million in gross proceeds, and the filing says pre-transaction Lisata stockholders will hold about 2.39% of the company's common stock after the financing, which substantially dilutes existing holders.
Lisata issued 1,793,129 common shares and 211,365.213 Series C preferred shares to Marea stockholders; each preferred share converts into 1,000 common shares, subject to Lisata stockholder approval
Concurrent private placement with a gross value of about $225 million; the investors will receive Series C preferred shares at about $1,491.37 per share
Post-financing ownership: pre-transaction Lisata holders about 2.39%, former Marea holders about 59.54%, private placement investors about 38.07%
Lisata's CEO is Dr. David J. Mazzo; Dr. Josh Lehrer was newly appointed President and Chief Operating Officer of Lisata
Lisata Therapeutics approved a reduction in workforce of approximately 72%, effective immediately, as it plans to pursue strategic options and cut ongoing operating expenses. The company expects about $1.2 million in severance and related termination costs through the quarter ending September 30, 2026, and its chief medical officer is departing. The company also sued Kuva Labs over alleged breach of a March 2026 merger agreement, seeking damages for expected stockholder benefits.
Workforce reduction of approximately 72%, effective immediately, approved by the Board on August 3, 2026
Estimated costs of approximately $1.2 million, expected through the quarter ending September 30, 2026
Dr. Kristen K. Buck, EVP of R&D and Chief Medical Officer, terminated effective August 3, 2026; contractually entitled to 12 months of base salary and target bonus, plus up to 12 months of COBRA premiums, subject to a release
Delaware Court of Chancery action filed July 31, 2026 against Kuva Labs Inc. and Kuva Acquisition Corp. over the Merger Agreement dated March 6, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every LISATA THERAPEUTICS, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →